Sanofi, Genzyme Boards Likely to Approve Takeover at About $74 p/sh : Report

Sanofi-Aventis SA (SNY) and Genzyme Corp. (GENZ) are likely to approve a takeover of the U.S. biotech company today and are discussing a price of about $74 a share plus potential additional payments tied to the performance of Genzyme’s experimental multiple sclerosis drug Lemtrada, said four people with knowledge of the plan. The co.’s boards are scheduled to vote on the deal today and may make an announcement on Feb. 7, said the people. – Bloomberg

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.